Mumbai-based longevity and preventive healthcare startup Vytalyou has raised ₹90 million in a Pre-Series A funding round from Chetan Jain of Pharma Dose and Ratan Jain of Venus Industries, two investors with established healthcare and industrial backgrounds. The investment values the company at approximately ₹330 million, according to the company. Vytalyou will use the fresh capital to expand its network of Incremental Lifestyle Clinics in Mumbai as it pursues a wider national presence in the preventive healthcare segment.
Funding and Expansion Plans
The company said the new capital will help it grow its Mumbai clinic network from the existing Powai facility to three centers. Over the coming years, Vytalyou plans to expand to 10 locations across India to widen access to its doctor-led care model. The expansion strategy is designed to establish a strong operational base in Mumbai before replicating the clinics in other urban markets.
A Doctor-Led Clinical Model
Founded in 2025 by molecular oncologist Dr. Chirantan Bose and radiologist Dr. Preetesh Bhandari, Vytalyou is building a network of doctor-led longevity clinics. Its model combines predictive diagnostics with personalized preventive therapies to help delay chronic lifestyle diseases and add healthy years to life. The company says it focuses on improving healthy life expectancy rather than simply managing late-stage illness, with every plan reviewed and supervised by physicians.
Predictive Evaluation and Medically Supervised Plans
The company's Predictive Longevity Evaluation uses an AI-based algorithm to assess an individual's health profile, biological aging, and potential future risks. Doctors review the results and develop a medically supervised plan tailored to each person. Depending on individual needs, the approach may include lifestyle guidance, further diagnostics, and therapies focused on cellular and mitochondrial health, with follow-ups to monitor progress.
Service Portfolio and Early Traction
Vytalyou's broader offering covers pathology, radiology, cardio-respiratory assessments, body composition evaluation, genetic and cancer screening, gut microbiome evaluation, personalized IV therapies, and regenerative interventions. It also provides non-invasive pain management technologies for chronic musculoskeletal conditions. The startup reports serving close to 1,000 clients since opening its first center, with about half arriving through walk-ins and the rest through word-of-mouth referrals.
Founder Perspective
Dr. Chirantan Bose said the company focuses on increasing healthy years of life rather than treating disease only after it appears. He added that the AI-based algorithm helps doctors build a comprehensive picture of an individual's organ systems and shape a personalized program. According to Bose, once the body's own cellular repair and regenerative mechanisms are reset, health can take a new trajectory.
Competitive Market Context
Vytalyou operates in India's expanding preventive healthcare and longevity segment, where several startups have recently secured investor backing. Biopeak raised US$2.7 million in follow-on funding in January this year, while Cent raised approximately US$5 million for its AI-led early-detection platform. Elevate Now and Decode Age have also raised capital, reflecting broader demand for early detection, biological aging insights, and longevity-focused care.
The new Pre-Series A funding gives Vytalyou resources to validate its clinic model in Mumbai before pursuing a wider national rollout. Its emphasis on AI-assisted assessment and physician oversight positions the company within a growing shift toward proactive and personalized healthcare in India. The investment reflects increasing confidence in longevity-focused models that aim to extend healthy years and reduce the burden of chronic disease.